What's the first step to a groundbreaking scientific discovery? The right team. At Unicon Pharma, we bring together the sharpest minds in life sciences to build teams that turn brilliant ideas into life-changing medicines. Learn more about how we can partner with you: - https://bit.ly/3C9VQSj #UniconPharmaInc #FirstStepToSuccess #InnovationInLifeSciences #LifeSciencesJourney #TogetherWeGrow
Unicon Pharma Inc’s Post
More Relevant Posts
-
A few words about the trends and challenges we see in Biotech nowadays, & how we propose to support innovation.
Get to know Joris Pezzini, our Executive Vice President in Biopharma. He helps biotech clients along the journey to reach their goals, structuring the drug development process into a series of clear and reachable value inflection points. Connect with him to discuss how we can help you bring your innovation to patients to address unmet medical needs. #biotech #biopharma
-
What factors will drive change and propel innovation over the next ten years? ATUM co-founder Claes Gustafsson provides a longer-term look at the future of #biopharma in Chapter 5 of The Medicine Maker's "The Multifaceted Future of Pharma" series. Check it out now! 👉 https://hubs.li/Q034TGcB0
-
-
The future of pharma is brimming with possibilities, from personalized medicine to AI-powered drug discovery. By embracing these advancements, we can create a healthier world for all. #InosTechnologies #PharmaInnovation #PersonalizedMedicine #pharmaceuticalindustry
-
One great marker of January is the annual article year review series Scrip Asks, published in the Citeline publication Scrip. In the free-to-access article 1, Eleanor Malone, Editor in Chief, Commercial Insights, and Joseph Haas, Senior Writer, discuss the 'State of the BioPharma Industry'. As Scrip is asking, one of the best spokespeople of 2024, Ali Pashazadeh answers. "Until the risk-reward of #pharmaceutical product invention and #clinical development improves materially, the industry is unlikely to attract incremental funds and therewith re-ignite development strategies that we were used to seeing in the few years before COVID..." Wouldn't be a new year without an answer from Vered Caplan, CEO, Orgenesis, as well, discussing how the #cellandgenetherapy sector can expand to further deliver #therapies to #patients. https://lnkd.in/eAXDGcWD
-
So looking forward to hearing the Pharma perspective at #BiotechShowcase as we had into so many industry changes coming in 2025 that will impact dealmaking!
📅Join us on Monday, 13 January at Biotech Showcase to hear from Adam Pearson from Astellas Pharma in the panel discussion ‘The Pharma Perspective: As We Emerge From A Challenging Few Years, What Has Changed in the Deal Landscape?’. This panel discussion will uncover the latest strategies and insights shaping the industry through discussion of effective approaches to forging successful partnerships and driving innovation in a competitive environment. 🔎Find out more about this session >> https://lnkd.in/eS6pFfTz Demy-Colton #BiotechShowcase #Pharma #DealLandscape #SanFrancisco
-
-
Imagine this: A world where every pharma breakthrough happens faster, better, and with precision. That’s what we do at Biolink CRO. We don’t just research—we create possibilities. We don’t just test—we redefine quality. Because for us, it’s not just about results. It’s about making a difference in the world of pharma. #PharmaInnovation #BiolinkCRO #Breakthroughs #ResearchToResults
-
-
David McErlane, Group President of Biologics, and Aris Gennadios, Group President of Pharma and Consumer Health, share their expert views on how Catalent has forged long-term collaborations and partnerships that drive innovation in the CDMO space. Their insights are featured in a recent article by CHEManager which dives into the latest trends shaping the industry, including advanced manufacturing technologies, new regulatory shifts, and the growing emphasis on sustainability. Read the article here: https://ow.ly/RAvf50TE8F7 #CDMO #Pharma #Biotech #Manufacturing #Innovation #Sustainability
-
-
David McErlane, Group President of Biologics, and Aris Gennadios, Group President of Pharma and Consumer Health, share their expert views on how Catalent has forged long-term collaborations and partnerships that drive innovation in the CDMO space. Their insights are featured in a recent article by CHEManager which dives into the latest trends shaping the industry, including advanced manufacturing technologies, new regulatory shifts, and the growing emphasis on sustainability. Read the article here: https://ow.ly/RAvf50TE8F7 #CDMO #Pharma #Biotech #Manufacturing #Innovation #Sustainability
-
-
Today’s #biotech and #pharma sponsors are facing rising costs, increased competition, and pressure to innovate faster than ever. To stay ahead, maximizing value at every stage of #drugdevelopment is critical—from early-stage research to #clinicaltrials and #commercialization. Join Thermo Fisher Scientific for an upcoming webinar where we’ll share findings from the Tufts Center for the Study of Drug Development on how integrating end-to-end #CDMO and #CRO services and solutions can significantly boost your program's #expectedNetPresentValue (eNPV). In this webinar, you'll learn: • The benefits of leveraging #eNPV modeling for combined #CDMO and #CRO services • How to streamline processes with #ThermoFisher’s Accelerator™ Drug Development • Real-world case studies showcasing successes from #biotech and #pharma sponsors Led by Dr. Joseph DiMasi from Tufts University, as well as Brenda Bruker and Brittany Hall from Thermo Fisher Scientific, this is a can’t-miss event. RSVP by clicking below: http://spr.ly/6046qxNbm
-
-
Join our webinar to learn the benefits of combining CRO and CDMO services through ThermoFisher's Accelerator™ Drug Development
Today’s #biotech and #pharma sponsors are facing rising costs, increased competition, and pressure to innovate faster than ever. To stay ahead, maximizing value at every stage of #drugdevelopment is critical—from early-stage research to #clinicaltrials and #commercialization. Join Thermo Fisher Scientific for an upcoming webinar where we’ll share findings from the Tufts Center for the Study of Drug Development on how integrating end-to-end #CDMO and #CRO services and solutions can significantly boost your program's #expectedNetPresentValue (eNPV). In this webinar, you'll learn: • The benefits of leveraging #eNPV modeling for combined #CDMO and #CRO services • How to streamline processes with #ThermoFisher’s Accelerator™ Drug Development • Real-world case studies showcasing successes from #biotech and #pharma sponsors Led by Dr. Joseph DiMasi from Tufts University, as well as Brenda Bruker and Brittany Hall from Thermo Fisher Scientific, this is a can’t-miss event. RSVP by clicking below: http://spr.ly/6046qxNbm
-
